Recent extremely meaningful negative changes in investment behavior have impacted Supernus Pharmaceuticals Inc (NASDAQ: SUPN): the stock’s recent price decline challenged its longer term uptrend, the stock fell on very heavy volume, and negative upside/downside volume developed.
Recent slight negative changes in fundamentals have impacted Supernus Pharmaceuticals Inc (NASDAQ: SUPN): significant quarterly earnings deceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
SUPN’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Supernus Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Supernus Pharmaceuticals has a neutral Power Rating of 49 and a neutral Appreciation Score of 47, triggering the Low Neutral Value Trend Rating.
Recent Price Action
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) stock closed at $27.87 on 5/22/24 after a slight decline of -0.6%. Moreover, this decline was accompanied by exceptionally high trading volume at 205% of normal. The stock has declined -3.8% during the last week and has performed in line with the market over the last nine months.
Be the first to comment